PTI is part of the Knowledge & Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Genotoxic Impurities - Strategies for Identification and Control

30 September - 1 October 2019

Radisson Blu Edwardian Grafton, London

The control of genotoxic impurities is crucial for ensuring regulatory compliance. With the implementation of increasingly stringent regulations for impurity levels, it is more important than ever for drug manufacturers to employ effective strategies for identifying, analysing and controlling GIs in their products.

Using a combination of theory and practical case studies, the course will allow delegates to develop the knowledge needed to overcome everyday problems and enhance performance, ensuring you are employing the most appropriate analytical strategies for your products.

This course is approved by the Royal Society of Chemistry, and is also available for studying online, check website for dates>>

  • Examining in detail the ICH guideline, its implications and its impact on  control strategies
  • Learning about current methods for assessing the risk posed by genotoxic impurities
  • Exploring crucial strategies for safety testing
  • Reviewing strategies for genotoxic impurity analysis
  • Practical advice for overcoming everyday problems through the use of case  studies and practical exercises

Andrew Teasdale

Andrew Teasdale, PhD, has over twenty years’ of experience in analytical chemistry and quality assurance and has published a number of papers relating to GIs as well as presented at a number of conferences. He has also led two expert groups working in the field of genotoxic impurities, including an analytical group in the UK and a Project Quality Research Institute (PQRI) working group, which focused on the critical area of sulfonate ester formation and control. He also led sub-groups within both EFPIA and PhRMA during the development of ICH M7 and currently leads a team developing the addendum to ICH M7 which will provide definitive limits for common mutagenic reagents.

This course is relevant to anyone involved in identifying / analysing / controlling / reporting of GTIs including those working in:

  • Analytical Chemistry/Validation/R&D
  • CMC
  • Development Chemistry
  • Genetic Toxicology
  • Impurities
  • Laboratory Management
  • Pharmaceutical Development
  • Regulatory Affairs
  • Safety Assessment
  • Toxicology

Specifications for Small Molecule Drug Products Webinar

Led by Dr Mark Powell, a Fellow of the Royal Society of Chemistry (RSC) with over 25 years’ experience as a senior analytical chemist. In 2013, Mark set up Mark Powell Scientific, a company that offers training and consultancy services in analytical chemistry.

The webinar will cover: 
• Regulatory guidance (ICH, FDA, EMA) 
• Tests appropriate to different dosage forms 
• Dissolution specifications for immediate-release, modified-release and extended-release drug products 
• Dissolution specifications in the context of the biopharmaceutical classification system 
• Control of polymorphism, enantiomeric purity, drug-related impurities and microbiological contamination 
• Specifications for combination drug products 
• The role of specifications in maximizing drug product stability

Andrew Teasdale speaking about the EMEA Guideline on the limits of Genotoxic Impurities

rsc approved training

This course is approved by the Royal Society of Chemistry for the purpose of continuing professional development.

As the UK’s professional body for chemical scientists, the Royal Society of Chemistry supports professional development by listing excellent training opportunities on their database of approved courses. The approval process is one of peer review, involving assessment against set criteria by members that are expert in their field.

you may also be interested in...